Publication date: October 2026 Source: European Urology Oncology, Volume 9, Issue 5 Author(s): Anwar R. Padhani, Sigrid Carlsson, Ola Bratt, Ivo G. Schoots
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126000611?dgcid=rss_sd_all
Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126000611?dgcid=rss_sd_all
“Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways.” European Urology Oncology.
@article{article89201,
title = {Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126000611?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...